Krajska Nemocnice T Bati a.s.
- Address
- lock Available on a paid plan
Analytical, Diagnostic, Therapeutic Techniques and Equipment – Surgical Procedures
The clinic conducts studies aimed at improving procedural safety and diagnostic accuracy for acute conditions, evaluating novel fluid‑management strategies during neurosurgery and assessing minimally invasive approaches for stroke and pulmonary embolism.
- Acute non‑cardioembolic ischemic stroke
- Intermediate‑high risk pulmonary embolism
- Elective neurosurgery for brain conditions
- Post‑operative complications after neurosurgical procedures
Krajska Nemocnice T Bati a.s. supports these technique‑focused trials to enhance patient outcomes.
Diseases – Cardiovascular Diseases
Trials target major heart and vascular events, testing innovative anti‑inflammatory and antithrombotic agents to reduce recurrence of myocardial infarction and prevent ischemic stroke after acute episodes.
- Anterior ST‑elevation myocardial infarction
- Non‑ST‑elevation myocardial infarction
- Ischemic stroke after transient ischemic attack
- Major adverse cardiovascular events (MACE)
Research at the oncology clinic integrates cardiovascular expertise to address these life‑threatening conditions.
Diseases – Digestive System Diseases
Studies evaluate the long‑term efficacy of biologic therapies for inflammatory bowel disorders, aiming to induce remission and improve quality of life for patients with Crohn’s disease and ulcerative colitis.
- Crohn’s disease
- Ulcerative colitis
- Moderately to severely active ulcerative colitis
The site’s multidisciplinary team collaborates to bring cutting‑edge treatments to patients with gastrointestinal inflammation.
Diseases – Neoplasms
Oncologic trials explore targeted and immunotherapies for various solid tumours, seeking better response rates and longer progression‑free survival in conditions such as non‑small cell lung cancer, ER+/HER2‑ advanced breast cancer, and head and neck squamous cell carcinoma.
- Non‑small cell lung cancer with HER2 mutation
- ER+/HER2‑ advanced breast cancer
- Head and neck squamous cell carcinoma
- Recurrent/metastatic solid tumours
Krajska Nemocnice T Bati a.s.’s oncology clinic leverages these trials to expand therapeutic options for cancer patients.
Diseases – Nervous System Diseases
Investigations focus on disease‑modifying agents for multiple sclerosis, aiming to slow disability progression and reduce relapse rates in both relapsing‑remitting and secondary progressive forms.
- Relapsing‑remitting multiple sclerosis
- Non‑relapsing secondary progressive multiple sclerosis
- Patients at high risk of disability progression
Through these studies, the clinic contributes to advancing neuro‑immunology treatments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 15 of 47 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 46 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1Eli Lilly & Co.3active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Eli Lilly & Co.3trials
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Krajska Nemocnice T Bati a.s.
lock Showing 1 of 22 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Janssen Cilag International | Phase III | Recruiting | Jan 2026 | — |
IMP list
lock Showing 1 of 47 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2024-10-23 | 2026-05-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.